The novel, nicotinic alpha7 receptor partial agonist, bms-933043, improves cognition and sensory processing in preclinical models of schizophrenia

HIGHLIGHTS

  • who: Linda J. Bristow et al. from the Lead Discovery and Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut, United States Editor: Kenji Hashimoto, Chiba University Center for have published the paper: The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia, in the Journal: PLOS ONE | DOI:10.1371/journal.pone [0159996]. July 28, 2016 of /1371/
  • what: In present studies the authors characterized agent (2R)-N-(6-(1H-imidazol-1-yl)-4-pyrimidinyl)-4'H-spir octane-2 5'-[1 3]oxazol]-2'-amine (BMS . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?